SCHEMBL3602979

SCHEMBL3602979

Cc1nc(NC(=N)N)sc1-c1cccc(NC(=O)CC(O)CC(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.45
MEN1 O00255 6/20 0.42
KMT2A Q03164 6/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 4/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
PIK3CG P48736 6/20 0.41
PIK3CD O00329 4/20 0.41
PIK3CA P42336 4/20 0.41
PIK3CB P42338 3/20 0.41
CASP3 P42574 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608529 0.91 XIAP (0.47) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3602477 0.88 XIAP (0.45) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL7144719 0.86 ALDH1A1 (0.49) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3605756 0.86 ALDH1A1 (0.49) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3593206 0.86 FNTA (0.46) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3602744 0.85 MEN1 (0.46) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3603149 0.85 MEN1 (0.48) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3611002 0.84 FNTA (0.48) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3602040 0.84 FNTA (0.43) XIAPMEN1KMT2AMAPTALDH1A1
SCHEMBL3602965 0.84 ITGB3 (0.43) XIAPMAPTALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US disclosed
CN-1224718-A Thiazole derivatives HOFFMANN LA ROCHE (CH) 1999-08-04 CN disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 XIAP 3269/4885MEN1 681/4885KMT2A 4510/4885
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 XIAP 4640/4885MEN1 3257/4885KMT2A 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.